Department of Neurology, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Norway.
Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway; Department of Global Public Health and Primary Care, University of Bergen, Norway.
J Neuroimmunol. 2019 Nov 15;336:577025. doi: 10.1016/j.jneuroim.2019.577025. Epub 2019 Aug 19.
The clinical relevance of antibodies that bind to glutamic acid decarboxylase 65 (GAD65) is controversial regarding diagnostic utility in screening for neurological disease or cancer. We did a retrospective study of 3152 GAD65 antibody-positive patients to examine whether analysis of the antibody levels could predict neurological disease or cancer. Serum GAD65 antibody levels were not associated with any of the following groups: neurological disease, neurological disease and diabetes, diabetes only, no neurological diagnosis and no diabetes mellitus, or cancer. Analysis of serum GAD65 antibody levels had no prognostic value in neurological disease or cancer. GAD65 antibodies should therefore be measured in selective cases of autoimmune neurological diseases.
谷氨酸脱羧酶 65（GAD65）抗体的临床相关性在用于筛查神经疾病或癌症方面的诊断效用存在争议。我们对 3152 例 GAD65 抗体阳性患者进行了回顾性研究，以检验抗体水平分析能否预测神经疾病或癌症。血清 GAD65 抗体水平与以下各组均无关联：神经疾病、神经疾病伴糖尿病、单纯糖尿病、无神经疾病诊断且无糖尿病、或癌症。血清 GAD65 抗体水平分析在神经疾病或癌症中没有预后价值。因此，GAD65 抗体应在自身免疫性神经疾病的选择性病例中进行测量。
